{
    "nct_id": "NCT03863704",
    "official_title": "Transcutaneous Vagal Nerve Stimulation to Treat Pediatric Inflammatory Bowel Disease",
    "inclusion_criteria": "1. Age 10-21 years\n2. IBD diagnosis for at least 3 months, confirmed by clinical, biochemical, and endoscopic evaluations\n3. Elevated Fecal calprotectin ≥ 200 ug/g within the past 4 weeks prior to enrollment\n4. Evidence of active inflammatory disease despite treatment with at least one conventional therapy\n5. If on corticosteroids, the dose must be stable and ≤ 10mg/day (prednisone or equivalent) for at least 14 days before entry into study\n6. If on 5-Aminosalicylate, dose must be stable with following parameters:\n\n   * 28 days on oral medication\n   * Prior to baseline calprotectin, 28 days on rectal medication or 2 weeks off rectal medication\n7. If on background immunosuppressive treatment the dose must be stable with the following parameters:\n\n   * 56 days (8 weeks) for Immunomodulators (methotrexate, 6-MP, Azathioprine)\n   * 112 days (16 weeks) for Infliximab, Adalimumab, Vedolizumab, Ustekinumab, other biologic\n8. Able and willing to give written informed consent and comply with the requirements of the study protocol.\nHealthy volunteers allowed\nMust have minimum age of 10 Years\nMust have maximum age of 21 Years",
    "exclusion_criteria": "1. Expectation to increase corticosteroids and/or immunosuppressive treatment\n2. Presence of bowel stricture with prestenotic dilatation\n3. Presence of intra-abdominal or perirectal abscess\n4. Pediatric UC activity Index (PUCAI) score ≥ 65 (severe)\n5. weighted Pediatric Crohn Disease Activity Index (wPCDAI) score > 57.5 (severe)\n6. Active treatment with antibiotics\n7. Presence of active intestinal infection or documented infection by stool PCR or culture analysis in the previous 6 weeks\n8. Continuous treatment with an anti-cholinergic medication, including over the counter medications\n9. Implantable electronic devices such as pacemakers, defibrillators, hearing aids, cochlear implants or deep brain stimulators.\n10. Current tobacco or nicotine user (to limit potential confounding effects of exposure to nicotine)\n11. Bowel resection surgery within past 90 days prior to study enrollment and on no conventional IBD therapy, or planned surgery within the course of the study\n12. Any planned surgical procedure requiring general anesthesia within the course of the study\n13. Participation in any other Investigational drug and/or treatment currently or planned during the length of the study\n14. Any condition which, in the opinion of the investigator, would jeopardize the subject's safety following exposure to a study intervention\n15. Pregnancy or Lactation\n16. Comorbid disease with high likelihood of requiring corticosteroid use\n17. Inability to comply with study and follow-up procedures\n18. Non-English speaking\n19. Known cardiac condition causing or with potential to cause arrhythmia",
    "miscellaneous_criteria": ""
}